In 2007, as well, Pollack et al. [109] assessed the MTD and the safety of imatinib, an ATP-competitive inhibitor of the BCR-ABL tyrosine kinase [110] with irradiation in pediatric patients with newly diagnosed brainstem gliomas and recurrent malignant gliomas. This evidence concerns the gene ABL1 and brain stem glioma.